Mary Wilson
Well-known member
20 July 2021
https://doi.org/10.7326/M21-1577
Adeel A. Butt, MBBS, MS, Saad B. Omer, MBBS, MPH, PhD, Peng Yan, MS, Obaid S. Shaikh, MD, Florian B. Mayr, MD, MPH
Abstract
Background:
With the emergency use authorization of multiple vaccines against SARS-CoV-2 infection, data are urgently needed to determine their effectiveness in a real-world setting.
Objective:
To evaluate the short-term effectiveness of vaccines in preventing SARS-CoV-2 infection.
Design:
Test-negative case–control study using conditional logistic regression.
Setting:
U.S. Department of Veterans Affairs health care system.
Participants:
All veterans who had testing for SARS-CoV-2 infection between 15 December 2020 and 4 March 2021 and no confirmed infection before 15 December 2020.
Intervention:
SARS-CoV-2 vaccination with either the BNT-162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine as part of routine clinical care.
...
https://www.acpjournals.org/doi/10.7326/M21-1577
https://doi.org/10.7326/M21-1577
Adeel A. Butt, MBBS, MS, Saad B. Omer, MBBS, MPH, PhD, Peng Yan, MS, Obaid S. Shaikh, MD, Florian B. Mayr, MD, MPH
Abstract
Background:
With the emergency use authorization of multiple vaccines against SARS-CoV-2 infection, data are urgently needed to determine their effectiveness in a real-world setting.
Objective:
To evaluate the short-term effectiveness of vaccines in preventing SARS-CoV-2 infection.
Design:
Test-negative case–control study using conditional logistic regression.
Setting:
U.S. Department of Veterans Affairs health care system.
Participants:
All veterans who had testing for SARS-CoV-2 infection between 15 December 2020 and 4 March 2021 and no confirmed infection before 15 December 2020.
Intervention:
SARS-CoV-2 vaccination with either the BNT-162b2 (Pfizer–BioNTech) or mRNA-1273 (Moderna) vaccine as part of routine clinical care.
...
https://www.acpjournals.org/doi/10.7326/M21-1577